Advertisement

Topics

Mage, LLC Company Profile

11:52 EST 12th December 2018 | BioPortfolio

Mage, LLC is a group of entrepreneurial business advisors who focus primarily on providing private and emerging companies with a broad range of business and organizational services. Unlike many other business consulting firms, Mage has the breadth and depth of services to identify and manage problems throughout an organization to help our clients grow. We are committed to strengthening an organization's ability to build long-term value and compete successfully in the marketplace by creating leadership, management and business excellence.Mage is at the forefront of organizational effectiveness and management development for emerging companies. Few consulting firms possess our level of commitment to our clients or our reputation for 'hands-on' creative problem solving and counsel.

Location

145 Rosemary Street
Needham
Massachusetts
02494
United States of America

Contact

Phone: 781-449-8366
Fax: 781-449-8301
Email: info@mageusa.com


News Articles [31 Associated News Articles listed on BioPortfolio]

Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress

PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented ini...

Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress

PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announc...

MAGE-A-Targeted Immunotherapy Competitor Analysis 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Competitor Analysis: MAGE-A-Targeted Immunotherapy” report has been added to ResearchAndMarkets.com’s offering. This Competitive Intelligence ...

$ADAP very disappointing data at #ESMO18 Both MAGE-A4 and MAGE-A10 TCR showed no response at all A10: 0% ORR in 11 pts, 7/11 SAEs A4: 0% ORR in 6pts, 4/6 SAEs http://globenewswire.com/news-release/2018/10/20/1624343/0/en/Updated-Data-from-Ongoing-MAGE

$ADAP very disappointing data at #ESMO18 Both MAGE-A4 and MAGE-A10 TCR showed no response at all A10: 0% ORR in 11 pts, 7/11 SAEs A4: 0% ORR in 6pts, 4/6 SAEs http://globenewswire.com/news-rele...

2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin” report has been added to ResearchAndMarkets.com’...

Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO

- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OX...

The First HLA Class II Restricted T Cell Receptor that Recognizes the Cancer Testis Antigen, MAGE-A3

NIH scientists have developed T cell receptors (TCRs) against the melanoma antigen family A3 (MAGE-A3) tumor antigen in the context of major histocompatibility complex (MHC) class II molecule HLA-DP-b...

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

Drugs and Medications [0 Results]

None

PubMed Articles [30 Associated PubMed Articles listed on BioPortfolio]

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC mela...

Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 T cell response in esophageal squamous cell carcinoma.

PD-1 is highly expressed on tumor-infiltrated antigen-specific T cells and limit the anti-tumor function. Blocking of PD-1/PD-L1 signaling have shown unprecedented curative efficacies in patients with...

miR‑34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGE‑A/p53 signaling.

The present study aimed to explore the combined role of microRNA (miR)-34a, melanoma antigen-A (MAGE‑A) and p53 in altering the chemosensitivity of retinoblastoma (RB) cells. Human RB and adjacent ...

MAGE-A antigens as targets for cancer immunotherapy.

Targeted anti-cancer therapies aim at reducing side effects while retaining their anti-cancer efficacy. Immunotherapies e.g. monoclonal antibodies, adoptive T cell therapy and cancer vaccines are used...

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Cancer Testis Antigens are immunogenic tumor-specific proteins. We investigated NY-ESO-1, MAGE-A3 and PRAME, in addition to WT1 expression in different Breast Cancer (BC) subtypes. We then evaluated t...

Clinical Trials [34 Associated Clinical Trials listed on BioPortfolio]

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

This study will investigate the safety and tolerability of MAGE A10ᶜ⁷⁹⁶T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose melanoma or bladder or head ...

A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Participants who are HLA-DPB1*04:01 positive and whose tumors are MAGE-A3/A6 positive may be eligible for this study. If eligible, white blood cells are collected by apheresis and genetica...

The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients

Considering the low expression rate of Melanoma-associated antigen 3 (MAGE-A3) in Asian especially Southeast Asian, it would be great interests to investigate the potential polymorphism of...

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours

This research is being done because these viruses have been shown to shrink tumours in animals and human tumour samples by selectively killing cancer cells and creating an immune response ...

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cuta...

Companies [4 Associated Companies listed on BioPortfolio]

Mage, LLC

Mage, LLC is a group of entrepreneurial business advisors who focus primarily on providing private and emerging companies with a broad range of business and organizational services. Unlike many other ...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and a...

COMMITE D EXPANSION.

En effet, l’Auvergne a inversé la tendance démographique qui la voyait perdre 1.300 habitants par an entre 1982 et 1998. Les premiers résultats du recensement INSEE confirment que la région a en...

Adaptimmune Limited

Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...

More Information about "Mage, LLC" on BioPortfolio

We have published hundreds of Mage, LLC news stories on BioPortfolio along with dozens of Mage, LLC Clinical Trials and PubMed Articles about Mage, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mage, LLC Companies in our database. You can also find out about relevant Mage, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record